Our Vision Our Approach Governance Disability Code Contact Us
بالعربية
0
Skip navigation links
Home
The Award
Family Village
Founders' Council
Research
Training & Events
About PSCDR
Disability Code
Our Partnerships
Video Library
0
0 0

Treatment of Myosclerosis in Children with Disability Using Botulinium Toxin

Completion date: 01 January 1996 


Principal Investigator
Dr. Talaat bin Hamza Al-Waznah 

Co-Investigators
None.


Research Outcome
Recommendations:
This drug was proved to reduce the myosclerosis and improve the functional performance of the patient.  The drug has no side effects. It was shown that the patient’s response to the drug is directly proportional to his mental abilities and inversely proportional to the patient’s age and the number of the stiffened muscle groups.


Grantee Institution
N/A.


Partners
Disabled Children Association


Publication list
N/A.


Other Resources
N/A.


Links
N/A.


0 0
© Prince Salman Center for Disability Research. All rights reserved. Staff email Executive portal Internal portal